Novo Nordisk posts web benefit beat as Wegovy gross sales bounce 107% in fourth quarter

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected web benefit within the fourth quarter, amid hovering call for for its Wegovy weight problems medication.

Web benefit for the fourth quarter got here in at 28.23 billion Danish kroner ($3.98 billion), as opposed to the 26.09 billion Danish kroner expected.

Complete-year web benefit reached 100.99 billion Danish kroner, additionally beating estimates of 99.14 billion Danish kroner for 2024.

The drug maker posted a 107% year-on-year building up in Wegovy gross sales to 19.87 billion Danish kroner ($2.76 billion) within the 3 months to the tip of December, relatively lacking the 20.02 billion Danish kroner forecast via analysts in a Factset ballot overdue Tuesday.

Novo Nordisk has ridden a flow of emerging world call for for GLP-1 agonist weight problems therapies. GLP-1s, which mode the foundation of Novo’s Wegovy and rival Eli Lilly‘s Zepbound, paintings via mimicking a hormone known as glucagon-like peptide-1, which suppresses urge for food.

Traders at the moment are staring at for updates at the corporate’s alternative weight problems drug applicants, together with its hotly expected experimental CagriSema remedy. Past due-stage CagriSema trial effects upset markets in December next demonstrating reasonable weight loss of twenty-two.7%, beneath the 25% Novo had in the past forecast.

The trial effects dealt a gamble away to expectancies that CagriSema would emerge as Novo’s next-generation weight problems drug, combining semaglutide — the energetic element in Wegovy — with amylin analog Cagrilintide, a nascent mode of weight reduction remedy.

On the other hand, sure early-stage effects for its as soon as weekly Amycretin weight problems drug, which in a similar way employs the amylin pancreas hormone, led the conserve upper terminating day.

It is a breaking information tale and might be up to date in a while.